We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Stryker (SYK) Q2 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts expect Stryker (SYK - Free Report) to post quarterly earnings of $3.46 per share in its upcoming report, which indicates a year-over-year increase of 10.5%. Revenues are expected to be $6.56 billion, up 8.9% from the year-ago quarter.
Over the last 30 days, there has been an upward revision of 0.8% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Stryker metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts' assessment points toward 'Net Sales by Business- MedSurg and Neurotechnology' reaching $3.59 billion. The estimate indicates a year-over-year change of -4.7%.
Analysts forecast 'Net Sales by Geography- Orthopaedics' to reach $2.96 billion. The estimate indicates a year-over-year change of +31.5%.
The collective assessment of analysts points to an estimated 'Net Sales by Business- MedSurg and Neurotechnology- Medical' of $1.04 billion. The estimate indicates a change of +5.6% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Sales by Geography- Orthopaedics- Trauma and Extremities' will likely reach $1.05 billion. The estimate points to a change of +9.6% from the year-ago quarter.
The consensus estimate for 'Net Sales by Business- MedSurg and Neurotechnology- Instruments' stands at $1.01 billion. The estimate indicates a year-over-year change of +31.7%.
Based on the collective assessment of analysts, 'Net Sales by Business- MedSurg and Neurotechnology- Endoscopy' should arrive at $946.68 million. The estimate indicates a change of +5.3% from the prior-year quarter.
Analysts predict that the 'Net Sales by Geography- Orthopaedics- Hips' will reach $496.90 million. The estimate points to a change of +6.6% from the year-ago quarter.
The consensus among analysts is that 'Net Sales by Business- MedSurg and Neurotechnology- Vascular' will reach $579.76 million. The estimate indicates a year-over-year change of +16.4%.
Analysts expect 'Net Sales by Geography- Orthopaedics- Knees' to come in at $690.28 million. The estimate points to a change of +7.9% from the year-ago quarter.
It is projected by analysts that the 'Net Sales by Geography- International' will reach $1.65 billion. The estimate indicates a change of +12.5% from the prior-year quarter.
The average prediction of analysts places 'Net Sales by Geography- United States' at $4.90 billion. The estimate suggests a change of +7.6% year over year.
Shares of Stryker have demonstrated returns of -0.7% over the past month compared to the Zacks S&P 500 composite's +0.8% change. With a Zacks Rank #3 (Hold), SYK is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Exploring Analyst Estimates for Stryker (SYK) Q2 Earnings, Beyond Revenue and EPS
Wall Street analysts expect Stryker (SYK - Free Report) to post quarterly earnings of $3.46 per share in its upcoming report, which indicates a year-over-year increase of 10.5%. Revenues are expected to be $6.56 billion, up 8.9% from the year-ago quarter.
Over the last 30 days, there has been an upward revision of 0.8% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Stryker metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts' assessment points toward 'Net Sales by Business- MedSurg and Neurotechnology' reaching $3.59 billion. The estimate indicates a year-over-year change of -4.7%.
Analysts forecast 'Net Sales by Geography- Orthopaedics' to reach $2.96 billion. The estimate indicates a year-over-year change of +31.5%.
The collective assessment of analysts points to an estimated 'Net Sales by Business- MedSurg and Neurotechnology- Medical' of $1.04 billion. The estimate indicates a change of +5.6% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Sales by Geography- Orthopaedics- Trauma and Extremities' will likely reach $1.05 billion. The estimate points to a change of +9.6% from the year-ago quarter.
The consensus estimate for 'Net Sales by Business- MedSurg and Neurotechnology- Instruments' stands at $1.01 billion. The estimate indicates a year-over-year change of +31.7%.
Based on the collective assessment of analysts, 'Net Sales by Business- MedSurg and Neurotechnology- Endoscopy' should arrive at $946.68 million. The estimate indicates a change of +5.3% from the prior-year quarter.
Analysts predict that the 'Net Sales by Geography- Orthopaedics- Hips' will reach $496.90 million. The estimate points to a change of +6.6% from the year-ago quarter.
The consensus among analysts is that 'Net Sales by Business- MedSurg and Neurotechnology- Vascular' will reach $579.76 million. The estimate indicates a year-over-year change of +16.4%.
Analysts expect 'Net Sales by Geography- Orthopaedics- Knees' to come in at $690.28 million. The estimate points to a change of +7.9% from the year-ago quarter.
It is projected by analysts that the 'Net Sales by Geography- International' will reach $1.65 billion. The estimate indicates a change of +12.5% from the prior-year quarter.
The average prediction of analysts places 'Net Sales by Geography- United States' at $4.90 billion. The estimate suggests a change of +7.6% year over year.
View all Key Company Metrics for Stryker here>>>Shares of Stryker have demonstrated returns of -0.7% over the past month compared to the Zacks S&P 500 composite's +0.8% change. With a Zacks Rank #3 (Hold), SYK is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .